CLEARSIDE DEVELOPED PROGRAMS
THERAPEUTIC
TYPE
INDICATION
CURRENT STATUS / PARTNER
THERAPEUTIC, TYPE, INDICATION, STATUS, PARTNER
XIPERE® / ARCATUS™
Corticosteroid (Triamcinolone Acetonide)
Uveitic Macular Edema2
(Asia Pacific ex-Japan)
XIPERE® / ARCATUS™
Corticosteroid (Triamcinolone Acetonide)
Diabetic Macular Edema2
(Asia Pacific ex-Japan)
SCS Microinjector® Partner Clinical Development Programs
THERAPEUTIC
TYPE
INDICATION
CURRENT STATUS / PARTNER
THERAPEUTIC, TYPE, INDICATION, STATUS, PARTNER
Bel-Sar
Viral-like Drug Conjugate
Choroidal Melanoma
ABBV-RGX-314
AAV Gene Therapy
Diabetic Retinopathy
ABBV-RGX-314
AAV Gene Therapy
Wet AMD
Avoralstat
Plasma Kallikrein Inhibitor
Diabetic Macular Edema
Footnotes:
1XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use has received U.S. FDA Approval and is being commercialized by Bausch + Lomb.
2In China, Arctic Vision is responsible for clinical development of ARCATUS™ (triamcinolone acetonide injectable suspension), formerly referred to as ARVN001, and known as XIPERE® in the U.S.